199 Biotechnologies

Executive Summary

199 Biotechnologies, a UK-based biotech founded in 2021, is pioneering therapies to extend healthy human lifespan by targeting the root cause of both cancer and aging: epigenetic damage. Unlike conventional approaches that destroy aberrant cells, the company redirects misprogrammed cells back to healthier states using a combination of partial reprogramming and senolytic compounds. Its integrated platform also includes a low-cost diagnostic service that enables monitoring of epigenetic age. By addressing the underlying epigenetic dysregulation, 199 Biotechnologies aims to provide a unified therapeutic strategy for age-related diseases. The company is currently in the pre-clinical stage, with a focus on validating its platform through in vitro and in vivo studies. Its novel approach differentiates it from other longevity biotechs, as it targets the common source of multiple diseases rather than individual indications. While still early-stage, the company's integrated diagnostic-therapeutic model could accelerate development and provide commercial revenue before therapies reach the market. Success in preclinical studies and securing funding for clinical translation will be key near-term milestones.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical proof-of-concept for lead reprogramming therapy70% success
• Q4 2026Commercial launch of epigenetic age diagnostic service80% success
• Q2 2026Series A funding round from longevity-focused investors60% success